The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
Yan Song, Tao Qu, Honggang Zhang, Yongkun Sun, Chengxu Cui, Yihebali Chi, Wen Zhang, Xingyuan Wang, Lin Yang Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beij...
Main Authors: | Song Y, Qu T, Zhang H, Sun Y, Cui C, Chi Y, Zhang W, Wang X, Yang L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-08-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/the-real-world-practice-of-fruquintinib-for-chinese-patients-with-meta-peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
by: Zhi Peng, et al.
Published: (2020-10-01) -
Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer
by: Zhang Y, et al.
Published: (2019-08-01) -
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
by: Rui-Hua Xu, et al.
Published: (2017-01-01) -
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
by: Qin S, et al.
Published: (2021-08-01) -
Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
by: Lei Wang, et al.
Published: (2020-11-01)